Allergy Immunotherapy Market is Projected to Reach USD 5.66 Billion by 2035

According to a new report published by Introspective Market Research, titled, “Allergy Immunotherapy Market by Type, Allergy Type, and Distribution Channel, The Global Allergy Immunotherapy Market Size Was Valued at USD 2.26 Billion in 2024 and is Projected to Reach USD 5.66 Billion by 2035, Growing at a CAGR of 8.70%. The global Allergy Immunotherapy Market is witnessing substantial growth, driven by the increasing prevalence of allergic diseases worldwide and rising awareness about long-term treatment options. Allergy immunotherapy (AIT), also known as desensitization or hypo-sensitization, is a preventive treatment for allergic reactions caused by substances such as pollen, insect venom, or dust mites. It works by gradually modifying the immune system’s response to allergens, reducing symptoms and improving quality of life compared to conventional pharmacotherapy.

AIT offers a disease-modifying approach rather than symptom relief, distinguishing it from traditional allergy medications. The market is gaining traction due to its long-term efficacy, potential to reduce future sensitizations, and sustained clinical benefits even after treatment completion. Growing healthcare expenditure, supportive government initiatives, and an increase in R&D activities to develop novel and more convenient immunotherapy formulations further boost market demand globally.

One of the primary factors driving the growth of the Allergy Immunotherapy Market is the rising incidence of allergic diseases worldwide. Factors such as urbanization, environmental pollution, and lifestyle changes have led to an increase in allergic conditions like asthma and allergic rhinitis. According to the World Allergy Organization, allergies affect over 20% of the global population, making allergy management a public health priority. Immunotherapy’s proven efficacy in offering long-term remission and disease-modifying benefits has accelerated its adoption among both patients and healthcare professionals.

A key opportunity in the Allergy Immunotherapy Market lies in the development of personalized and peptide-based therapies. Ongoing clinical research is focusing on improving treatment specificity and reducing adverse effects. Technological advancements, such as novel allergen extracts and recombinant DNA-based immunotherapies, are expected to enhance safety profiles and treatment adherence. Additionally, the expanding acceptance of sublingual immunotherapy (SLIT) due to its convenience and non-invasive administration offers lucrative growth potential, particularly in home-based treatment models.

Allergy Immunotherapy Market, Segmentation

Type

  • The Type segment is further classified into Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT) Tablets, and SLIT Drops. Among these, the Sublingual Immunotherapy (SLIT) Tablets segment accounted for the highest market share in 2024. This dominance is attributed to the rising preference for non-invasive treatments, better patient compliance, and reduced need for clinical supervision. SLIT tablets have become the preferred option for patients seeking convenience and safety, contributing significantly to market expansion.

Allergy Type

  • The Allergy Type segment is further classified into Asthma, Allergic Rhinitis, Food Allergy, and Others. Among these, the Allergic Rhinitis sub-segment held the largest market share in 2024. The rising global prevalence of allergic rhinitis, driven by increasing air pollution and changing climatic conditions, has intensified the demand for effective long-term treatment solutions. Immunotherapy provides durable relief by addressing the underlying cause rather than symptoms, thereby improving patient outcomes.

Some of The Leading/Active Market Players Are:

  • ALK-Abelló A/S (Denmark)
  • Stallergenes Greer (France)
  • Allergy Therapeutics PLC (United Kingdom)
  • LETI Pharma (Spain)
  • HollisterStier Allergy (United States)
  • Torii Pharmaceutical Co., Ltd. (Japan)
  • ASIT Biotech SA (Belgium)
  • HAL Allergy Group (Netherlands)
  • Circassia Group PLC (United Kingdom)
  • DBV Technologies (France)
  • Anergis SA (Switzerland)
  • Roxall Medizin GmbH (Germany)
  • Biomay AG (Austria)
  • Jubilant HollisterStier (United States)
  • other active players.

Key Industry Developments

  • In February 2024, ALK-Abelló A/S launched a next-generation sublingual immunotherapy tablet targeting multiple pollen allergies in Europe. The innovation aims to simplify multi-allergen management, offering enhanced convenience and efficacy in seasonal allergy control.

  • In June 2023, Stallergenes Greer announced the expansion of its immunotherapy manufacturing facility in France to meet rising global demand. The expansion is expected to strengthen its production capabilities and ensure timely supply of personalized allergy treatment solutions.

Key Findings of the Study

  • Sublingual Immunotherapy (SLIT) Tablets segment dominated the market in 2024.
  • Allergic Rhinitis remained the leading allergy type globally.
  • Europe held a significant market share owing to advanced healthcare infrastructure.
  • Rising prevalence of allergies and growing R&D in personalized immunotherapy drive market growth.
  • Technological advancements are fostering the development of safer and more effective treatments.

Share On :

Posted by  T Kumbhar

T. Kumbhar is a results-driven Senior Market Research Consultant at IMR, specializing in market trends, competitive intelligence, and data-driven insights. With extensive experience across Agrochemicals, Food Tech, Consumer Goods, Automotive, and Construction, he helps businesses make informed strategic decisions through in-depth research and analysis. His expertise includes market research, competitive analysis, business strategy, forecasting, pricing strategies, and consumer insights.